Home/Filings/4/0001209191-16-100020
4//SEC Filing

FIBROGEN INC 4

Accession 0001209191-16-100020

$FGENCIK 0000921299operating

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 5:17 PM ET

Size

13.3 KB

Accession

0001209191-16-100020

Insider Transaction Report

Form 4
Period: 2016-02-16
VALONE FRANK H MD
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2016-02-16$2.90/sh+2,492$7,22799,332 total
  • Exercise/Conversion

    Common Stock

    2016-02-16$3.50/sh+8,258$28,903107,590 total
  • Sale

    Common Stock

    2016-02-16$18.41/sh10,750$197,94396,840 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2016-02-168,25831,742 total
    Exercise: $3.50Exp: 2021-06-07Common Stock (8,258 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2016-02-162,4927,508 total
    Exercise: $2.90Exp: 2020-06-09Common Stock (2,492 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    4,000
Footnotes (4)
  • [F1]Shares sold pursuant to a 10b5-1 plan.
  • [F2]The shares were sold at prices between $18.0122 and $18.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Twenty percent of the shares subject to each option vests on the first anniversary of the vesting commencement date and 80% of the shares subject to each option vests in 16 substantially equal quarterly installments thereafter over for the following four years.
  • [F4]Fully vested.

Issuer

FIBROGEN INC

CIK 0000921299

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000921299

Filing Metadata

Form type
4
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 5:17 PM ET
Size
13.3 KB